Abstract
Psoriasis is a common skin disorder associated with number of serious medical comorbidities negatively impacting quality of life in involved individuals. Development of therapeutic approaches resulted in introduction of biological forms of management in severe diseases.
Simultaneously research resulted in discovery of immunomodulating agent capable to interrupt pathological cascade of inflammatory process. Apremilast presents an innovative oral targeted PDE4 inhibitor competent to modulate broad spectrum of inflammatory mediators in psoriasis.
Its introduction results in reduction of inflammatory pathology in skin and in joints favourably affecting clinical symptoms. This article reviews data on mechanism of action and on results of different clinical trials in efficacy and safety of apremilast in management of psoriatic disorders.
